
HEALEY ALS Platform Trial

Weekly Q&A – Oct 14, 2021



MGH	MASSACHUSETTS
1811	GENERAL HOSPITAL



Sean M. Healey & AMG Center for ALS at Mass General







































The Arthur M. Blank FAMILY FOUNDATION





Guest Speaker

David Walk, MD FAAN University of Minnesota, MN Platform Trial Site Investigator



University of Minnesota Platform Trial Staff



David Walk Site Investigator



Sarah Hilbert Research Manager



Valerie Ferment Research Coordinator



Cat Koukol Research Coordinator



Sam Maiser Site Co-Investigator




Carly Schroeder Research Coordinator/ Evaluator

Twin Cities ALS Research Consortium



Perpetual Adaptive Trial Shared Placebo; Randomization Ratio 3:1 Open Label Extension (OLE) offered



Enrollment Updates (as of October 14, 2021)

- 803 individuals with ALS signed informed consent
- 636 individuals were assigned to a regimen
- 571 individuals were randomized within a regimen (active or placebo)
- 230 have entered the Open Label Extension (OLE)

• 155 individuals were randomized within Regimen A = 162

- 167 individuals were randomized within Regimen B = 167
- 161 individuals were randomized within Regimen C = 161
- 88 individuals were randomized within Regimen D = 109


Thank You

This breakthrough trial would not be possible without your partnership

Participants in screening

Total randomized +

How to Find a Center Near You



52 sites are actively enrolling

Contact Info of Participating Sites by State

https://www.massgeneral.org/neurology/als/research/platform-trial-sites

as of 10/14/21 7

Patient Navigator



Catherine Small Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

To see whether you might qualify, view the list of eligibility criteria: https://bit.ly/3p4PrLL





Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites





Upcoming Guest Speakers:

Oct 21st- Xiaowei (Bill) Su, MD, PhD (Penn State Health, PA) Oct 28th- Megan Miller, PhD (IAMALS Director of Science and Policy)